Literature DB >> 8781141

Comparison of uptake of 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 into human breast cancer cell lines.

M de Jong1, B F Bernard, W A Breeman, G Ensing, H Benjamins, W H Bakker, T J Visser, E P Krenning.   

Abstract

Technetium-99m hexakis-2-methoxyisobutylisonitrile (MIBI), 99mTc-tetrofosmin and 99mTc-Q12 were all introduced for myocardial imaging but found additional applications as they are taken up by different tumours, enabling imaging of these lesions in patients. The aim of this study was to compare the uptake characteristics of these compounds in vitro in the human adenocarcinoma breast cell lines MCF-7 and ZR-75. It was shown that 99mTc-MIBI had the highest cellular uptake (15.9%+/-0.5% dose/mg protein after 60 min in MCF-7, and 14.2%+/-0.4% dose/mg protein in ZR-75), followed by 99mTc-tetrofosmin (6.8%+/-0.6% dose/mg protein in MCF-7, and 8. 2%+/-0.2% dose/mg protein in ZR-75) and 99mTc-Q12 (3.2%+/-0.1% dose/mg protein in MCF-7, and 3.5%+/-0.3% dose/mg protein in ZR-75 cells). For all three compounds tenfold differences in specific activity did not influence total cell-associated radioactivity. Uptake of 99mTc-MIBI and 99mTc-tetrofosmin was obviously lower at 4 degrees C than at 37 degrees C, whereas 99mTc-Q12 uptake showed only slight temperature dependence. When uptake was compared in cells grown to different cell densities (1 mg/ml cellular protein versus 0.3 mg/ml), no differences in uptake were detected when uptake was corrected for the amount of cellular protein present in the dishes. Furthermore, for all compounds it was shown that cellular radioactivity decreased rapidly after washing. Apart from the differences in cellular uptake of the three compounds after 60 min, no differences in residual cellular radioactivity after washing were found between the different compounds when expressed as a percentage of their 60-min uptake, suggesting that the efflux process of the radiolabelled compounds was similar. The differences in cell-associated activity after 60 min were thus presumably caused by differences in uptake. It was concluded that of the Tc-labelled compounds tested, 99mTc-MIBI had the highest cellular retention in both human breast tumour cell lines. However, for imaging in vivo not only radioactivity in the target organ is important, but also the ratio of radioactivity in the target versus that in the background. Therefore, further studies in vivo need to be performed to investigate which compound is the optimal imaging agent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781141     DOI: 10.1007/bf01367592

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  11 in total

1.  99Tcm sestamibi--a new agent for parathyroid imaging.

Authors:  A J Coakley; A G Kettle; C P Wells; M J O'Doherty; R E Collins
Journal:  Nucl Med Commun       Date:  1989-11       Impact factor: 1.690

2.  Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes.

Authors:  D Piwnica-Worms; B L Holman
Journal:  J Nucl Med       Date:  1990-07       Impact factor: 10.057

3.  Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.

Authors:  L I Delmon-Moingeon; D Piwnica-Worms; A D Van den Abbeele; B L Holman; A Davison; A G Jones
Journal:  Cancer Res       Date:  1990-04-01       Impact factor: 12.701

4.  Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts.

Authors:  M L Chiu; J F Kronauge; D Piwnica-Worms
Journal:  J Nucl Med       Date:  1990-10       Impact factor: 10.057

5.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

Authors:  D Piwnica-Worms; M L Chiu; M Budding; J F Kronauge; R A Kramer; J M Croop
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

6.  Evaluation of palpable breast masses with 99Tcm-MIBI: a comparative study with mammography and ultrasonography.

Authors:  Z Burak; M Argon; A Memiş; S Erdem; Z Balkan; Y Duman; E E Ustün; Y Erhan; H Ozkiliç
Journal:  Nucl Med Commun       Date:  1994-08       Impact factor: 1.690

7.  Magnetic resonance imaging for assessment of treatment effects in mediastinal Hodgkin's disease.

Authors:  R Nyman; S Rehn; B Glimelius; H Hagberg; A Hemmingsson; B Jung
Journal:  Acta Radiol       Date:  1987 Mar-Apr       Impact factor: 1.990

8.  Biological studies of a new class of technetium complexes: the hexakis(alkylisonitrile)technetium(I) cations.

Authors:  A G Jones; M J Abrams; A Davison; J W Brodack; A K Toothaker; S J Adelstein; A I Kassis
Journal:  Int J Nucl Med Biol       Date:  1984

9.  Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging.

Authors:  F J Wackers; D S Berman; J Maddahi; D D Watson; G A Beller; H W Strauss; C A Boucher; M Picard; B L Holman; R Fridrich
Journal:  J Nucl Med       Date:  1989-03       Impact factor: 10.057

10.  99Tcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant.

Authors:  J R Ballinger; H A Hua; B W Berry; P Firby; I Boxen
Journal:  Nucl Med Commun       Date:  1995-04       Impact factor: 1.690

View more
  3 in total

1.  Brain tumor imaging with 99mTc-tetrofosmin: comparison with 201Tl, 99mTc-MIBI, and 18F-fluorodeoxyglucose.

Authors:  J Y Choi; S E Kim; H J Shin; B T Kim; J H Kim
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

2.  99m Tc-sestamibi scintimammography in detection of recurrent breast cancer.

Authors:  Zvezdana Rajkovaca; Goran Vuleta; Amela Matavulj; Peda Kovacević; Nenad Ponorac
Journal:  Bosn J Basic Med Sci       Date:  2007-08       Impact factor: 3.363

3.  Study of the cytotoxicity of asiaticoside on rats and tumour cells.

Authors:  Fatma J Al-Saeedi
Journal:  BMC Cancer       Date:  2014-03-25       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.